Innovation Pharmaceuticals Inc (IPIX)

[Golfguru03]

Latest repurposed anti-inflammatory drug for the Coronavirus failed..

BRIEF
Novartis rare disease drug, repurposed for COVID-19, fails in late-
By Ben Fidler Biopharma Dive
Published Nov. 6, 2020



The Novartis anti-inflammatory medicine canakinumab failed to help patients hospitalized with COVID-19 in a Phase 3 clinical trial, the Swiss drugmaker reported Friday.

Cytokine Storm or Cytokine Release Syndrome (CRS)..remains a leading cause for mortalities in hospitalized patients with Covid-19..

NOTE: The last sentence was mine..

Mark

#Brilacidin